Compare Organon & Co. Common Stock (OGN) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Target Corporation — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Target Corporation trades at $155.45 (market cap $69.05B). The key difference: Target Corporation is far larger — about 19.1× Organon & Co. Common Stock's market cap, and Target Corporation pays the higher dividend (3.05%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Target Corporation for 137 Days on average.
| OGN | TGT | |
|---|---|---|
Market Cap | $3.62B | $69.05B |
Volume | 2,892,999 | 3,728,482 |
Sector | Health | Consumer Staples |
52-Week High | $13.81 | $169.90 |
52-Week Low | $5.70 | $83.68 |
Typical Hold Time | 0 Days | 137 Days |
Enterprise Value | $11.04B | $82.33B |
Dividend Yield | 0.58% | 3.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Target (TGT) trades at $155.30, up 1.13% today, with a neutral technical signal and key resistance at $155. The stock shows strong profitability with a 26.41% ROE and 4.08% net margin, supported by three consecutive quarterly earnings beats. Recent news highlights holiday price cuts to capture market share, while analyst consensus is evenly split between Buy and Hold ratings.
The outlook is balanced: valuation appears reasonable with a P/E of 15.77, and dividend stability offers income appeal, but competitive pressures and margin compression from aggressive pricing pose risks. Upside to the $166.95 consensus target depends on successful execution of growth initiatives amid a challenging retail environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
